AbbVie Inc.

ABBV-N

Get Alerts80 watching

NYSE:ABBV

75.39
0.34 (0.45%)
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories.
More at Wikipedia
ABBV Fundamental Data  by TradingView
ABBV Chart  by TradingView
Technical Analysis for ABBV  by TradingView

Analysis and Opinions about ABBV-N

Signal
Opinion
Expert
WAIT
WAIT
AbbVie Inc. (ABBV-N)
February 6, 2020
Trades at 38x earnings. Great dividend yield. Prefers something like JNJ, as it has 3 divisions. With pharma, you need these blockbuster drugs. If the pipeline is weak, the stock falls. Much more difficult to own in an election year, as they're the easiest scapegoat. Pharma usually pops up after an election.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 6, 2020
Trades at 38x earnings. Great dividend yield. Prefers something like JNJ, as it has 3 divisions. With pharma, you need these blockbuster drugs. If the pipeline is weak, the stock falls. Much more difficult to own in an election year, as they're the easiest scapegoat. Pharma usually pops up after an election.
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$87.180
Owned
Unknown
BUY
BUY
AbbVie Inc. (ABBV-N)
February 3, 2020
He likes it. There's a new uptrend after a long downtrend since early 2018. He's like to see strong volumes and support at $80. If so, it could touch $90.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 3, 2020
He likes it. There's a new uptrend after a long downtrend since early 2018. He's like to see strong volumes and support at $80. If so, it could touch $90.
0 Comments
Javed Mirza

Unlock Ratings

Price
$82.300
Owned
Unknown
BUY
BUY
AbbVie Inc. (ABBV-N)
January 17, 2020
On international drug pricing, it is one of the proposals from Trump. The reason why it's coming to the forefront is because they haven't been able to accomplish anything. The proposal is to initiate a pilot project. Their highest selling drug, Humira, has concerns of patent dispute. He saw the Allergen acquisition as a positive for diversifying the risk from the potential dispute.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
January 17, 2020
On international drug pricing, it is one of the proposals from Trump. The reason why it's coming to the forefront is because they haven't been able to accomplish anything. The proposal is to initiate a pilot project. Their highest selling drug, Humira, has concerns of patent dispute. He saw the Allergen acquisition as a positive for diversifying the risk from the potential dispute.
0 Comments
Paul MacDonald

Unlock Ratings

Price
$88.000
Owned
Yes
COMMENT
COMMENT
AbbVie Inc. (ABBV-N)
November 28, 2019
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 28, 2019
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
0 Comments
Bruce Murray

Unlock Ratings

Price
$88.330
Owned
No
TOP PICK
TOP PICK
AbbVie Inc. (ABBV-N)
November 27, 2019
Acquiring Allergan. Knock on it was that Humera made up 60% of revenues. Purchase of Allergan dilutes that concentration, and will be 10% accretive in Year 1. Expected revenue growth of 10%, whereas peer group is 3.1%. Trading at less than 10x. Free cashflow, after the dividend, of over 5%. Compelling opportunity. Yield is 5.34%. (Analysts’ price target is $95.45)
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 27, 2019
Acquiring Allergan. Knock on it was that Humera made up 60% of revenues. Purchase of Allergan dilutes that concentration, and will be 10% accretive in Year 1. Expected revenue growth of 10%, whereas peer group is 3.1%. Trading at less than 10x. Free cashflow, after the dividend, of over 5%. Compelling opportunity. Yield is 5.34%. (Analysts’ price target is $95.45)
0 Comments
Gordon Reid

Unlock Ratings

Price
$88.330
Owned
Yes
DON'T BUY
DON'T BUY
AbbVie Inc. (ABBV-N)
August 2, 2019
Has gone down a lot due to arthritis drug coming off patent. Earnings have been disappointing which pushed down the price further. Unsure if they can rebuild revenues to the same levels as before. Competition is now coming from generics and biosimilars, and would prefer medical device companies.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 2, 2019
Has gone down a lot due to arthritis drug coming off patent. Earnings have been disappointing which pushed down the price further. Unsure if they can rebuild revenues to the same levels as before. Competition is now coming from generics and biosimilars, and would prefer medical device companies.
0 Comments
David Driscoll

Unlock Ratings

Price
$65.310
Owned
No
DON'T BUY
DON'T BUY
AbbVie Inc. (ABBV-N)
July 25, 2019
Avoid this one. Made a plan to do a very large acquisition, because their core line is declining. Allocating capital, and taking on debt, to mask a problem, and that's a red flag. Value trap.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 25, 2019
Avoid this one. Made a plan to do a very large acquisition, because their core line is declining. Allocating capital, and taking on debt, to mask a problem, and that's a red flag. Value trap.
0 Comments
Christopher Blumas

Unlock Ratings

Price
$66.660
Owned
No
COMMENT
COMMENT
AbbVie Inc. (ABBV-N)
July 18, 2019

Issue is that longer run pipeline is coming to an end. The quest is always for the next big drug out there. Trying to buy Allergan, whose big thing is botox. Political pressure on lower drug prices. Monster yield of over 6.5%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 18, 2019

Issue is that longer run pipeline is coming to an end. The quest is always for the next big drug out there. Trying to buy Allergan, whose big thing is botox. Political pressure on lower drug prices. Monster yield of over 6.5%.

0 Comments
Bryden Teich

Unlock Ratings

Price
$68.250
Owned
Unknown
COMMENT
COMMENT
AbbVie Inc. (ABBV-N)
July 18, 2019

Good news, bad news. Dividend is beautiful, Q1 beat, cheap valuation, raised outlook for 2019. Problem is it's really levered to Humira, so a one-trick pony. Trying to buy Allergan to diversify. Likes it at a lower level, but cautious. Not really for an RRSP. (Analysts’ price target is $83.70)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 18, 2019

Good news, bad news. Dividend is beautiful, Q1 beat, cheap valuation, raised outlook for 2019. Problem is it's really levered to Humira, so a one-trick pony. Trying to buy Allergan to diversify. Likes it at a lower level, but cautious. Not really for an RRSP. (Analysts’ price target is $83.70)

0 Comments
Greg Newman

Unlock Ratings

Price
$68.250
Owned
Unknown
HOLD
HOLD
AbbVie Inc. (ABBV-N)
July 17, 2019
Abbvie has Humira, an $18-20 billion arthritis drug that will lose patent protection. ABBV bought Allergan under pressure to diversify--they needed to. They at 7.5x earnings with little growth after 2021. The Allergan purchase won't add much growth, but will lessen risk; Abbvie won't need to rely so much on Humira for revenues. The Allergan deal isn't done yet, but he likes it. Likes ABBV's dividend.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 17, 2019
Abbvie has Humira, an $18-20 billion arthritis drug that will lose patent protection. ABBV bought Allergan under pressure to diversify--they needed to. They at 7.5x earnings with little growth after 2021. The Allergan purchase won't add much growth, but will lessen risk; Abbvie won't need to rely so much on Humira for revenues. The Allergan deal isn't done yet, but he likes it. Likes ABBV's dividend.
0 Comments
Paul MacDonald

Unlock Ratings

Price
$68.320
Owned
Yes
BUY
BUY
AbbVie Inc. (ABBV-N)
July 9, 2019
It's come off a lot, so there's opportunity. He doesn't know the stock well, but the chart suggests a buy right now.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 9, 2019
It's come off a lot, so there's opportunity. He doesn't know the stock well, but the chart suggests a buy right now.
0 Comments
Elliott Fishman

Unlock Ratings

Price
$71.240
Owned
Unknown
BUY
BUY
AbbVie Inc. (ABBV-N)
May 3, 2019

Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
May 3, 2019

Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.

0 Comments
Paul MacDonald

Unlock Ratings

Price
$78.710
Owned
Unknown
DON'T BUY
DON'T BUY
AbbVie Inc. (ABBV-N)
April 22, 2019
A fine company. Its major product is Humira, the biggest drug in the world in terms of sales and it amounts to 65% of ABBV's revenue. ABBV's dividend is sound, but ABBV will have to go through a transition, like merge with another comapny and develop other drugs, to take the pressure off Humira.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 22, 2019
A fine company. Its major product is Humira, the biggest drug in the world in terms of sales and it amounts to 65% of ABBV's revenue. ABBV's dividend is sound, but ABBV will have to go through a transition, like merge with another comapny and develop other drugs, to take the pressure off Humira.
0 Comments
Gordon Reid

Unlock Ratings

Price
$78.150
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
AbbVie Inc. (ABBV-N)
April 4, 2019
(A Top Pick Apr 12/18, Down 7%) The only big pharma name that has a single digit P/E. Nice dividend yield over 5%. It is under pressure now because their arthritis drug is facing competition from generics and it is 60% of their revenues. The dividend yield acts as a support now. He is holding and monitoring M&A activity.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 4, 2019
(A Top Pick Apr 12/18, Down 7%) The only big pharma name that has a single digit P/E. Nice dividend yield over 5%. It is under pressure now because their arthritis drug is facing competition from generics and it is 60% of their revenues. The dividend yield acts as a support now. He is holding and monitoring M&A activity.
0 Comments
Stan Wong

Unlock Ratings

Price
$82.810
Owned
Yes
HOLD
HOLD
AbbVie Inc. (ABBV-N)
March 21, 2019
They have Humera which makes up 62% of their revenue. This is not up-coming in the business but it represents some patent risk as it comes off patent in 4 years in the US. There will be competition around the world before then but not significant. They have to back stop this with other offerings. It could be through a purchase of a pipeline or something else. As time goes on you are going to get less and less benefit from this drug as an investment.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 21, 2019
They have Humera which makes up 62% of their revenue. This is not up-coming in the business but it represents some patent risk as it comes off patent in 4 years in the US. There will be competition around the world before then but not significant. They have to back stop this with other offerings. It could be through a purchase of a pipeline or something else. As time goes on you are going to get less and less benefit from this drug as an investment.
0 Comments
Gordon Reid

Unlock Ratings

Price
$81.240
Owned
Unknown
Showing 1 to 15 of 54 entries
Next Page

AbbVie Inc.(ABBV-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 3

Total Signals / Votes : 9

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 9 stock analysts published opinions about ABBV-N. 5 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is WAIT. Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by Paul Harris, CFA on 2020-02-06. Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

9 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2020-04-07, AbbVie Inc. (ABBV-N) stock closed at a price of $75.39.

© Stockchase Inc.